UNSPSC 51272106: Meprylcaine

This classification denotes an anesthetic agent with the molecular formula C14H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82YT7WU9PW, chemically known as 1-propanol, 2-methyl-2-(propylamino)-, benzoate (ester) but generally known as meprylcaine, which bears US NIH Compound Identifier 4065. European Medicines Agency schedules Meprylcaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08760MIG.

UNSPSC 51272106 Meprylcaine is a Commodity code that captures pharmaceutical ingredients and active pharmaceutical components procured by state and local health agencies, though recent opportunities show state and local jurisdictions more actively soliciting finished pharmaceutical products—naloxone, generic multi-source medications, and over-the-counter products—rather than raw chemical compounds. State and local buyers under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple states and local government facilities. The work being solicited ranges from community health procurement of specific finished pharmaceuticals (naloxone and drug deactivation systems for harm reduction) to large-scale multi-state cooperative purchasing of generic and OTC medications distributed through authorized wholesale channels to state and local healthcare facilities.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capability information on direct-to-manufacturer prescription programs for the state's pharmacy benefit system, reflecting a shift toward supply-chain innovation rather than traditional wholesale distribution. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 to establish multi-award contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors responding to MMCAP must maintain relationships with authorized wholesalers and demonstrate compliance with FDA manufacturing standards, Drug Supply Chain Security Act requirements, and 3 percent administrative fee structures.